In the present study, we aimed to investigate the cytotoxicity of DEAB and the recently discovered ALDH-affinic compounds [21] on several ALDH1A3-expressing breast and prostate cancer cell lines as single agents, and in combination with DOX to evaluate the possibility of enhancing sensitization to DOX treatment. This evidence concerns the gene ALDH1A3 and prostate carcinoma.